D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
MONROVIA, CA - Invizyne Technologies, Inc., a company specializing in enzyme-based biomanufacturing systems, has announced its corporate rebranding to eXoZymes, Inc. The change will be reflected in the stock market with a new ticker symbol, EXOZ, which is expected to start trading on February 12, 2025, pending final approvals. The announcement comes as the stock has experienced a 14.66% decline over the past week, according to InvestingPro data.
The biomanufacturing firm, previously trading on NASDAQ under the ticker IZTC, is known for its innovative approach to producing biochemicals such as Active Pharmaceutical (TADAWUL:2070) Ingredients (APIs), biofuels, and other commercial products through cell-free, enzyme-based systems. This method is seen as a potential alternative to traditional chemical synthesis, natural extraction, and synthetic biology techniques. With a market capitalization of $153.13 million, the company currently appears overvalued according to InvestingPro Fair Value analysis, which offers 8 additional key insights about the company’s financial health and prospects.
As part of the rebranding, eXoZymes will update its corporate website and other branding materials. Existing shareholders will not need to take any action regarding the name and ticker symbol change. The company’s common stock CUSIP number will remain the same, as confirmed by the Committee on Uniform Securities Identification Procedures.
This move comes as the company aims to better reflect its strategic focus and technological advancements in the field of biomanufacturing. The information is based on a press release statement from the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.